Innovative drug out-licensing deal count vs First-in-class drug approvals in China
In 2025, innovative drug out-licensing deal count in China stood at 150, against 11 for first-in-class drug approvals.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Innovative drug out-licensing deal count and First-in-class drug approvals
Unit: count · 6 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Innovative drug out-licensing deal count | 2025 | Actual | 150 |
| Innovative drug out-licensing deal count | 2024 | Actual | 94 |
| First-in-class drug approvals | 2025 | Actual | 11 |
| First-in-class drug approvals | 2024 | Actual | 48 |
| First-in-class drug approvals | 2023 | Actual | 40 |
| First-in-class drug approvals | 2022 | Actual | 21 |
Shared periods
Side by side
Only 2 periods are published for both series in China. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Innovative drug out-licensing deal count
Total number of out-licensing transactions concluded for innovative pharmaceutical products.
2 observations in China · source organisations: NHSA
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations in China · source organisations: NMPA, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring